Ralph B. Arlinghaus
16Patents
10h-index
19Co-inventors
69Inventor score
Filing activity: Jun 20, 1989 → Dec 19, 2012
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5128319A | Prophylaxis and therapy of acquired immunodeficiency syndrome | Physics | 40 | Expired |
| US6265539A | Prophylaxis and therapy of acquired immunodeficiency syndrome | Physics | 27 | Expired |
| US5369008A | Methods for the detection of BCR-ABL and abnormal ABL proteins in leukemia patients | Emerging Cross-Sectional Technologies | 26 | Expired |
| US6656471B1 | HIV-specific T-cell induction | Emerging Cross-Sectional Technologies | 22 | Expired |
| US6107457A | Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth | Human Necessities | 19 | Expired |
| US5603933A | CD4 peptides for binding to viral envelope proteins | Chemistry; Metallurgy | 15 | Expired |
| US7306804B2 | HIV-specific T-cell induction | Emerging Cross-Sectional Technologies | 12 | Expired |
| US7319000B1 | Compositions and methods for eliciting immune or anti-infective responses | Chemistry; Metallurgy | 11 | Expired |
| US7220853B2 | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1 | Chemistry; Metallurgy | 11 | Expired |
| US7309692B1 | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1 | Chemistry; Metallurgy | 10 | Expired |
| US7923548B2 | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1 | Chemistry; Metallurgy | 9 | Active |
| US8338366B2 | Bioactive FUS1 peptides and nanoparticle-polypeptide complexes | Chemistry; Metallurgy | 7 | Active |
| US6210873A | Methods and compositions for the priming of specific cytotoxic T-lymphocyte response | Emerging Cross-Sectional Technologies | 6 | Expired |
| US5126399A | Methods and compositions for the preparation and use of site-directed immunologic reagents | Chemistry; Metallurgy | 4 | Expired |
| US8859727B2 | Bioactive FUS1 peptides and nanoparticle-polypeptide complexes | Chemistry; Metallurgy | 1 | Active |
| US6537804B1 | BCR-ABL directed compositions and uses for inhibiting Philadelphia chromesome stimulated cell growth | Human Necessities | 1 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.